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Abstract
Background: Modified Gingyo-san (MGS) is empirically used to treat various respiratory infections. MGS has been
reported to have antiinflammatory and antiviral activities; however, it is not known if it has an antibacterial activity.
Therefore, in this study, we aimed to investigate the antimicrobial activity of MGS against respiratory pathogens.
Methods: MGS, which is sold as an over-the-counter drug in Japan, was used for the study. Antimicrobial activity
was evaluated using the disk diffusion method. Growth inhibitory activity was evaluated by measuring colony-
forming units of the pathogens in the presence of MGS.
Results: MGS inhibited the growth of Bacillus subtilis, Streptococcus pneumoniae, and Streptococcus pyogenes, which
are gram-positive bacteria. Although the growth of most gram-negative bacteria was not inhibited by MGS,
interestingly, the growth of Haemophilus influenzae was inhibited. MGS did not show any activity against Candida
albicans or bacteriophage φX174.
Conclusions: In addition to the antiinflammatory and antiviral activities of MGS, which have already been reported,
the data obtained from this study indicates that MGS has an antibacterial activity.
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Background
Respiratory infections are mainly caused by viruses or bac-
teria. Particularly, Streptococcus pneumoniae, Haemophi-
lus influenzae, and Streptococcus pyogenes are the major
causative bacteria of respiratory infections. In several cases
of respiratory infections, the aforementioned bacteria
cause severe invasive infections [1–3]. Furthermore, these
bacteria are developing resistance to the currently used
antimicrobial agents, which can result in various clinical
concerns [4]. This indicates the urgent need for develop-
ing novel antimicrobial agents.
Until recently, the use of traditional medicines was
focused mainly in alternative medicine. In traditional
Chinese medicine, herbal medicines are used for the
treatment of various respiratory infections. However, the
use of such medicines is based on experience and is not
supported by basic scientific evidence. These medicines
have, however, been applied in many clinical settings. In
recent years, many researchers have made efforts to estab-
lish basic scientific evidences for the use of several herbal
medicines used in traditional Chinese medicine because of
evidence-based treatment. For example, it has been
reported that Sho-sei-ryu-to and Ma-o-to have antiviral
activities against the influenza virus [5–7]. Gingyo-san
(GS) has also been reported to have antiviral activity
against influenza virus and an immunomodulating activity
[8–11]. Modified Gingyo-san (MGS) and GS are sold as
over-the-counter (OTC) drugs. MGS is used to treat sore
throats, coughs, and headaches. GS and MGS are
composed of the crude drugs shown in Table 1. The indi-
vidual components of MGS have been studied by several
researchers. The roots of glycyrrhiza and platycodon,
which are included in MGS, have been reported to have
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antiinflammatory and antitussive activities [12, 13]. In
addition, schizonepeta spike and forsythia fruit have
antibacterial activities against Propionibacterium acnes
and thus, they are used for treating acne [14–16].
Therefore, MGS has a potential use in the treatment of
various symptoms of infectious diseases. In this study, we
evaluated the direct effects of MGS on pathogenic bacteria
to establish a basic evidence of its antibacterial activity.
Methods
Microbial strains and culture conditions
The microbial strains used in this study are listed in
Table 2. All the microbes, except the streptococci and H.
influenzae, were cultured using Mueller-Hinton broth or
agar (Oxoid Ltd., Hampshire, UK). The streptococci and
H. influenzae were cultured using blood agar or Todd-
Hewitt broth (Oxoid Ltd.) and chocolate agar or brain
heart infusion broth (Oxoid Ltd.) supplemented with
Table 1 Formulations of modified Gingyo-san and Gingyo-san




Lonicerae Flos 4.26 30.0
Forsythiae Fructus 4.26 30.0
Glycyrrhizae Radix 2.56 15.0
Platycodi Radix 2.56 18.0
Menthae Herba 2.56 18.0
Arctii Fructus 2.14 18.0
Schizonepetae Spica 1.7 12.0
Fermented soybean 2.14 12.0
Lophatherum Herba 1.7 15.0
Antelope Horns 0.13 -
aextract
bdaily dose























Quality control strain for susceptibility
test
Bacillus subtilis ATCC6633 Control strain for various assays
Gram-negative bacteria
Escherichia coli ATCC25922 Quality control strain for susceptibility
test
Escherichia coli C Host of bacteriophage φX174
Pseudomonas aeruginosa
ATCC27853












Quality control strain for various assays
Bacteriophage
φX174 Virulent phage for E. coli C
Table 3 Inhibitory zone of modified Gingyo-san containing
paper diska
Strain Inhibitory zone (mm)b
Staphylococcus aureus JCM2874 -
Staphylococcus aureus N315 -
Streptococcus pneumoniae ATCC49619 10.0
Streptococcus pneumoniae 19F 10.0
Streptococcus pyogenes JCM5674 8.5
Enterococcus faecalis ATCC29212 -
Bacillus subtilis ATCC6633 -
Escherichia coli ATCC25922 -
Pseudomonas aeruginosa ATCC27853 -
Haemophilus influenzae ATCC49247 -
a8 mg/disk
b- , inhibitory zone not appeared
Fig. 1 Antibacterial effect of modified Gingyo-san against Bacillus subtilis
ATCC6633. This experiment was performed twice on independent
occasions and similar results were obtained. The data shown is
representative of the results obtained
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15 μg/mL of nicotinamide adenine dinucleotide solution
and 15 μg/mL of hemin solution, respectively.
Disk diffusion method
MGS was obtained from ISKRA Industry (Tokyo, Japan).
The disk diffusion antimicrobial test was conducted as
follows. Briefly, 8-mm paper disks were impregnated
with MGS suspension to obtain 8 mg of MGS/disk. The
bacteria were suspended in 0.75% agar containing
Mueller-Hinton broth and poured into suitable petri
dishes. The disks were placed on the set agar and the
plates were incubated at 35 °C overnight, after which the
zones of growth inhibition were measured.
Evaluation of growth inhibitory activity
A single colony of bacteria was inoculated into the
appropriate broth medium and incubated at 37 °C over-
night. The culture was diluted with the broth (1:100),
with or without MGS, and incubated at 37 °C with shak-
ing. A 100-μL of the culture was sampled at 0, 1, 2, 4,
and 6 h after incubation and diluted with phosphate-
buffered saline (PBS). Serial dilutions were then plated
on the appropriate agar plates and incubated at 37 °C
overnight. Afterwards, the numbers of grown colonies
were counted. All the experiments were performed at
least twice on independent days. It was also confirmed
that all the experiments showed similar results.
Fig. 2 Antibacterial effects of modified Gingyo-san against several bacterial strains. a S. aureus JCM2874; b S. aureus N315 (MRSA); c S. pneumoniae
ATCC49619; d S. pneumoniae 19F; e S. pyogenes JCM5674; f E. faecalis ATCC29212; g E. coli ATCC25922; h P. aeruginosa ATCC27853; and i
H. influenzae ATCC49247. Each experiment was performed three times on independent occasions and similar results were obtained. The
P value was calculated by Welch’s t-test. ** P < 0.01, *P < 0.05
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Plaque assay
MGS was mixed with bacteriophage φX174. The mix-
tures were diluted with PBS and further mixed with
Escherichia coli C and 0.75% agar. The mixtures were
then poured onto nutrient agar and incubated at 37 °C
for 12 h, after which the plaques were counted.
Cell proliferation assay
Cell proliferation activities with or without MGS were
performed using CellTiter 96 Aqueous One Solution Cell
Proliferation Assay Kit (Promega, Madison, MI, USA).
Monolayer human lung epithelial cell lines (A549 cells)
were grown using Eagle’s minimal essential medium, to
which 10% fetal calf serum had been added, in 96-well
plates. Aliquots of MGS were then added and the plates
were incubated at 37 °C for 3 h under 5% CO2. After incu-
bation, the numbers of living cells were determined using
the kit according to the manufacturer’s instructions [17].
Statistical analysis
We assessed statistical significance of differences for growth
in the presence or absence of MGS. We performed Student’s
and Welch’s t-tests using JMP software (SAS Institute Inc.,
NC, USA). P < 0.05 were judged as significant difference.
Results and discussion
Antimicrobial activity of MGS
The disk diffusion method is used as a screening test for
the antimicrobial activities of drugs and natural products
[18, 19]. The susceptibility disk method was therefore
used to determine whether MGS has antimicrobial activity
(Table 3). Zones of growth inhibition were obtained in the
experiments involving S. pneumoniae and S. pyogenes but
not in those involving the other pathogens. This data
indicates that MGS has a direct antibacterial activity
against S. pneumoniae and S. pyogenes.
Growth inhibitory activity of MGS against respiratory
pathogens
The susceptibility disk test is suitable for screening the anti-
microbial activities of drugs; however, not all drugs that
have antimicrobial activities produce zones of growth inhib-
ition, which may be due to the chemical properties of the
drugs [20]. Therefore, to validate the growth inhibitory
effect of MGS, bacterial colony-forming units (CFUs) in
cultures were monitored over time in the presence or ab-
sence of MGS. The number of CFUs of B. subtilis
ATCC6633, which is normally used for testing the antibac-
terial activity of drugs, decreased in a dose-dependent man-
ner after the addition of MGS to the culture medium
(Fig. 1). MGS is usually administered with approximately
100 mL of water; thus, after administration, the concentra-
tion of MGS in the oral cavity reaches approximately
24 mg/mL. Since MGS was used at a concentration equiva-
lent to its usually administered dose, the data obtained indi-
cates that MGS has a direct antibacterial effect at its
normal dose.
The antimicrobial activity of MGS was analyzed at a con-
centration was 20 mg/mL. The growth of S. aureus, S.
pneumoniae, S. pyogenes, and Enterococcus faecalis was sig-
nificantly inhibited by the addition of MGS to the respect-
ive culture media (Fig. 2). MGS also inhibited the growth of
antimicrobial-resistant strains such as methicillin-resistant
S. aureus (MRSA) and penicillin-resistant S. pneumoniae
(PRSP) (Fig. 2). Therefore, these results indicate that MGS
has growth inhibitory effects against gram-positive bacteria.
However, the growth of E. coli and Pseudomonas aerugi-
nosa was not inhibited (Fig. 2). In addition, MGS did not
affect other gram-negative bacteria such as Acinetobacter
Fig. 3 Antifungal and antibacteriophage effects of modified Gingyo-san. a C. albicans ATCC10231 and b bacteriophage φX174. Each experiment
was performed 3 times on independent occasions and similar results were obtained
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baumannii, Serratia marcescens, and Klebsiella pneumo-
niae (data not shown).
However, interestingly, the growth of H. influenzae,
which is a major causative pathogen of respiratory infec-
tions, was significantly inhibited in spite of it being a
gram-negative bacterium (Fig. 2). It has been reported
that among gram-negative bacteria, H. influenzae has a
different cell surface structure [21]. In addition, the
chromosomal efflux pumps of H. influenzae are fewer
than those of other gram-negative bacteria [22]. The
aforementioned factors might therefore be related to the
observed bactericidal effect of MGS on H. influenzae in
this study. These findings indicate that MGS can com-
prehensively inhibit the growth of respiratory bacterial
pathogens. Moreover, MGS showed inhibitory effects
against MRSA and PRSP, which suggests that MGS
could be a very useful antibiotic for the treatment of re-
spiratory infections.
Effects of MGS on Candida albicans and bacteriophage
φX174
The inhibitory effects of MGS on eukaryotes and viruses
were analyzed using Candida albicans and bacteriophage
φX174 as the eukaryotic and viral models, respectively (Fig. 3).
The data obtained indicated that MGS does not inhibit the
growth of C. albicans or bacteriophage φX174. In addition,
MGS did not show any antiproliferative effects against the
A549 cells (Fig. 4). These findings indicate that MGS might
not have any direct effect on eukaryotes or viruses.
Conclusions
Our study indicated that MGS has a direct antibacterial
effect against respiratory bacterial pathogens. These
findings together with those from previous reports show
that, GS has in vivo antiviral activity against the influ-
enza virus and that MGS could be a useful antibacterial
agent. Therefore, MGS may be effective for use as a
pastille and a gargle. Moreover, future studies need be
conducted to clarify whether the metabolites of MGS as
well have effects on bacteria.
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